Requests that the FDA remove from the market the injectable contraceptive Depot Medroxyprogesterone Acetate (DMPA; Depo Provera) based on conclusive evidence that it uniquely facilitates the transmission of HIV from men to women and has other known risks. Numerous alternatives are available.
🏛 Food and Drug Administration (FDA)FDA-2026-P-2641
Documents
0
Total comments
0
all analyzed
Comment status
Closed
Last activity
—
In this docket
Documents
Rules, notices, and supporting material — the primary rule pinned first.
No documents mirrored for this docket yet.